CAMBRIDGE, Mass., & WASHINGTON--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company will release to the public molecular profiles of pediatric cancers currently maintained as part of FoundationCore™, the company’s information knowledgebase. FoundationCORE is one of the largest and most robust collections of common and rare clinical tumor profiles globally. The release of this data is part of the company’s ongoing effort to stimulate and accelerate research and development of much needed precision oncology therapies to treat all cancers, including pediatric cancers. The announcement of the data release, which is the first-of-its-kind from FoundationCORE, was announced today at the Precision Medicine Initiative Summit held at the White House.
